Five commonly used hematology tests, treatments, and procedures are not always necessary, according to the Choosing Wisely® initiative of the ABIM (American Board of Internal Medicine) Foundation. The American Society of Hematology (ASH) Choosing Wisely list of these five tests was...
Obinutuzumab (Gazyva) plus chlorambucil (Leukeran) was superior to rituximab (Rituximab) plus chlorambucil as first-line therapy in older chronic lymphocytic leukemia (CLL) patients with comorbidities, with an acceptable safety profile, according to final results of the phase III CLL11 trial....
The intensity of transplant-related chemotherapy and radiation has effects on cognition, according to a study presented at the 55th American Society of Hematology (ASH) Annual Meeting and Exposition (Abstract 913). Full-intensity hematopoietic stem cell transplant was associated with cognitive...
Development of autologous genetically engineered anti-CD19 chimeric antigen receptor (CAR)-expressing T cells holds promise in the treatment of hematologic malignancies. CAR T cells are being studied in adult and pediatric acute lymphocytic leukemias and in chronic lymphocytic leukemia, and...
Although imatinib (Gleevec) is the initial therapy for chronic myeloid leukemia (CML), several second-generation tyrosine kinase inhibitors are now approved for the treatment of this disease. Michael Millenson, MD, of Fox Chase Cancer Center in Philadelphia, reviewed practical considerations in...
Interim positron emission tomography (PET) scan is being used to guide risk-adapted therapy in patients with early-stage and advanced-stage Hodgkin lymphoma for clinical research at academic centers, and experts predict that this will become standard of care in clinical practice. At the NCCN 8th...